Search Results - Application+%3e+Research+Materials

655 Results

Sort By:

Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2

Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is seeking potential licensees interested in further developing or utilizing these Casq2 mouse strains. As a research tool, patent protection is not being pursued for this technology. More information to access these strains can be found here: https://www.jax.org/strain/036291...

Published: 9/29/2025 | Inventor(s): Karl Pfeifer, Bjorn Knollmann

Keywords(s):

Category(s): TherapeuticArea > Rare/Neglected Diseases, Application > Research Materials, Collaboration Sought > Licensing

Rapid Spectral Unmixing Using Spectrally Interpolated Background Reduction (SIBR) for Fluorescence Imaging

This breakthrough technology introduces Spectrally Interpolated Background Reduction (SIBR), a novel process that enables the rapid and efficient calculation of fluorescence signals from individual probes in complex, multi-labeled samples. Unlike traditional methods that require extensive computational power, SIBR provides real-time unmixing of signals...

Published: 9/22/2025 | Inventor(s): Harshad Vishwasrao

Keywords(s):

Category(s): Application > Medical Devices, Application > Research Materials, Application > Diagnostics

C8166-45 Cells

Summary: The National Cancer Institute (NCI) seeks licensees for a human T-cell line, C8166-45, transformed by HTLV-1. C8166-45, also known as C63/CRII-2, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth. Description of Technology: ...

Published: 8/21/2025 | Inventor(s): Genoveffa Franchini, Syed Salahuddin, Flossie Wong-Staal, Robert Gallo, Phillip Markham, V Kalyanaraman

Keywords(s):

Category(s): Application > Research Materials, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing

T Cell Receptor Targeting HPV6 E2 and a Panel of Cos7 Cells Expressing Different HLA Class I Proteins for Use in Validation and Potency Studies

Summary: The National Cancer Institute (NCI) seeks licensees for this invention comprising (1) a novel T cell receptor (TCR) specific to the E2 protein of Human papillomavirus (HPV) type 6 in the context of the human leukocyte antigen, HLA-B55, and (2) a panel of Cos7 cells expressing different HLA proteins for validation of T cell responses in immunotherapies...

Published: 8/21/2025 | Inventor(s): Clint Allen, Scott Norberg

Keywords(s):

Category(s): Application > Research Materials, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Vascularized Thyroid-on-a-Chip for Personalized Drug Screening and Disease Modeling

This technology includes a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. By permitting real-time perfusion of nutrients, hormones, and immune cells, the platform...

Published: 7/15/2025 | Inventor(s): Anagha Rama Varma, Parnika Kant, Kaitlyn Sadtler, Parinaz Fathi, Nicole Morgan, Paniz Rezvan Sangsari, Madison Daminato

Keywords(s):

Category(s): Application > Diagnostics, Application > Medical Devices, Application > Research Materials, Application > Therapeutics, ResearchProducts > Human Cell Lines, ResearchProducts > Research Equipment, TherapeuticArea > Endocrinology, TherapeuticArea > Immunology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Establishment and characterization of the A 1847 human ovarian carcinoma line

Summary: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage. Description of Technology: Mutations,...

Published: 6/27/2025 | Inventor(s): Stuart Aaronson, Nelson Ellmore (Estate)

Keywords(s):

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials

First in class Small Molecule Agonists of the mammalian Relaxin family receptor 1 (RXFP1) and use in treatment of cancer, fibrotic, and vascular disorders (HHS Ref No. E-145-2024-0-US-02)

It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory...

Published: 5/30/2025 | Inventor(s): Juan Marugan, Mark Henderson, Kenneth Wilson, Wenwei Huang, Wenjuan Ye, Noel Southall, Jiankang Jiang, Khalida Shamim, Bing Li, Alexander Agoulnik, Abhijeet Kapoor, Joshua Hutcheson, Ana Cabrera, Irina Agoulnik

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology, TherapeuticArea > Cardiology, TherapeuticArea > Pulmonology, TherapeuticArea > Dermatology, TherapeuticArea > Reproductive Health, TherapeuticArea > Geriatrics

Antibodies to TMC1 Protein for Hearing Loss

This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1...

Published: 5/19/2025 | Inventor(s): Andrew Griffith, Tomoko Makishima, Valentina Labay

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, ResearchProducts > Antibodies, Collaboration Sought > Licensing, Collaboration Sought > Materials Available

Bioplatform to Identify and Characterize Pathogens and Therapies against Tuberculosis and Other Granulomatous Diseases.

Treatment for human tuberculosis (TB) and other granulomatous diseases would benefit from high- throughput screening (HTS)-compatible platform replicating physiological conditions in hallmark granuloma lesions. However, currently available screening platforms and 2-D and 3-D cell culture systems lack throughput and key features, and relevant microenvironments...

Published: 5/9/2025 | Inventor(s): Suraj Sable, James Posey, Wen Li, Allison Kline

Keywords(s):

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

In-vivo System to Interrogate the Functions of Mucous Membranes and Identify Mucin/Glycan Mimetics and JAK/STAT Inhibitors for the Treatment of Diseases of the Oral Cavity and Digestive Tract

This technology includes a Drosophila mutant strain that can be used as an in vivo model for diseases of the oral cavity and digestive tract (Sjogren's syndrome, colitis, colon cancer, inflammatory bowel disease), where the mucous membrane is disrupted or non-functional. This mutant lacks a mucous membrane and displays epithelial cell damage, uncontrolled...

Published: 12/26/2024 | Inventor(s): Liping Zhang, Kelly Ten Hagen

Keywords(s): FUNCTIONS, IDENTIFY, Inhibitors, Interrogate, Jak/STAT, MEMBRANES, MIMETICS, Mucin/glycan, Mucous, System, Vivo, VPXXXX, WIXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Cardiology

1 2 3 4 5 6 7 8 9 10 ...